Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elgendy Akram Y, Saver Jeffrey L, Amin Zahid, Boudoulas Konstantinos Dean, Carroll John D, Elgendy Islam Y, Grunwald Iris Q, Gertz Zachary M, Hijazi Ziyad M, Horlick Eric M, Kasner Scott E, Kent David M, Kumar Preetham, Kavinsky Clifford J, Liebeskind David S, Lutsep Helmi, Mojadidi Mohammad K, Messé Steven R, Mas Jean-Louis, Mattle Heinrich P, Meier Bernhard, Mahmoud Ahmad, Mahmoud Ahmed N, Nietlispach Fabian, Patel Nimesh K, Rhodes John F, Reisman Mark, Sommer Robert J, Sievert Horst, Søndergaard Lars, Zaman Muhammad O, Thaler David, Tobis Jonathan M
Аннотация
OBSERVATIONS: Randomized clinical trials have demonstrated that, to prevent recurrent ischemic stroke in patients with PFO and an otherwise-cryptogenic index ischemic stroke, PFO closure is superior to antiplatelet medical therapy alone; these trials have provided some evidence that, among medical therapy options, anticoagulants may be more effective than antiplatelet agents.
CONCLUSIONS AND RELEVANCE: These new data indicate a need to update classification schemes of causative mechanisms in stroke, developed in an era in which an association between PFO and stroke was viewed as uncertain. We propose a revised general nomenclature and classification framework for PFO-associated stroke and detailed revisions for the 3 major stroke subtyping algorithms in wide use.